Feasibility of [[sup.18]F]FDG PET/MRI with Early-Delayed and Extended PET as One-Stop Imaging for Staging and Predicting Metastasis in Rectal Cancer

Background: We aimed to evaluate the diagnostic accuracy of 2-[[sup.18]F]-fluoro-2-deoxy-D-glucose positron emission tomography/magnetic resonance imaging ([[sup.18]F]FDG PET/MRI) for preoperative staging and usefulness of the detection of extramural vascular invasion (EMVI) for predicting metastasi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncology 2022-04, Vol.100 (4), p.212
Hauptverfasser: Morikawa, Mitsuhiro, Goi, Takanori, Seto, Shun, Tsujikawa, Tetsuya, Sawai, Katsuji, Okazawa, Hidehiko, Kurebayashi, Hidetaka
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 4
container_start_page 212
container_title Oncology
container_volume 100
creator Morikawa, Mitsuhiro
Goi, Takanori
Seto, Shun
Tsujikawa, Tetsuya
Sawai, Katsuji
Okazawa, Hidehiko
Kurebayashi, Hidetaka
description Background: We aimed to evaluate the diagnostic accuracy of 2-[[sup.18]F]-fluoro-2-deoxy-D-glucose positron emission tomography/magnetic resonance imaging ([[sup.18]F]FDG PET/MRI) for preoperative staging and usefulness of the detection of extramural vascular invasion (EMVI) for predicting metastasis in rectal cancer. Methods: Twenty-three patients underwent pretreatment [[sup.18]F]FDG PET/MRI, including early-delayed and extended PET and dedicated pelvic MRI without using anticonvulsant or contrast agents. Seven patients received preoperative treatment and all subsequently underwent surgery. Clinical cancer stages were evaluated using postoperative histopathology as a reference. PET/MR-defined EMVI (pmrEMVI) and pathological (p) TN stages were correlated with disease progression for a maximum of 2 years. Results: Of 16 patients without preoperative treatment, 10 had pT3, 4 tumors, 7 had pN1-3 lymph nodes, and 5 had synchronous metastases (SM; liver, lung, inguinal node). The sensitivity, specificity, and accuracy of PET/MRI were 90%, 67%, and 81% for T staging (T1, 2 vs. T3, 4), and 89%, 100%, and 94% for N staging (N0 vs. N1-3), respectively. Patient-based accuracy for SM staging was 100% (4/4). Of 23 patients, 6 were positive for pmrEMVI and 4 had metachronous metastases or local recurrence (MM; pelvic node, brain, lung, skin) during the follow-up periods. Five of the 6 pmrEMVI-positive patients had SM and/or MM (odds ratio = 37.5). Among pT, pN, and pmrEMVI, pmrEMVI-positivity was the only significant predictor for poorer progression-free survival (p < 0.05). Conclusions: [[sup.18]F]FDG PET/MRI according to our suggested protocol is a one-stop, non-contrast, and valid diagnostic method for rectal cancer staging, and pmr­EMVI can be used as an imaging biomarker for predicting metastases. Keywords: Positron emission tomography/magnetic resonance imaging, Rectal cancer, Staging, Extramural vascular invasion, Metastasis
doi_str_mv 10.1159/000522205
format Article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A709902688</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A709902688</galeid><sourcerecordid>A709902688</sourcerecordid><originalsourceid>FETCH-LOGICAL-g598-b3f5f6816cdd695ffa2810c61778b21d2ea6c07ce11f37536ec28ae0efea5cbf3</originalsourceid><addsrcrecordid>eNpNjE1rwkAQhnNoodb20H-wUOgturtx83EUTaygKOpNRCab2bglbiS70vo_-oMbsQdhYObhfeb1vDdGe4yJpE8pFZxzKh68DqUB9fmADZ68Z2u_2igSg7Dj_WYIVue60u5CakW2W3s-9Vi8y3bZeEKW6aY_X03Jt3YHkkJTXfwxVnDBgoApSPrj0BQttB4BSxYG_bWrT2R6hFKbkqi6IWt3u68PywYLLd0V5-jAtqMt0YasUDqoyAiMxObFe1RQWXz9311vk6Wb0ac_W0ymo-HML0US-3mghApjFsqiCBOhFPCYURmyKIpzzgqOEEoaSWRMBZEIQpQ8BqSoEITMVdD13m-1JVS410bVrgF51FbuhxFNEsrDOG6tjzvrgFC5g62rs9O1sffiHw5FcI4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Feasibility of [[sup.18]F]FDG PET/MRI with Early-Delayed and Extended PET as One-Stop Imaging for Staging and Predicting Metastasis in Rectal Cancer</title><source>Karger Journals</source><creator>Morikawa, Mitsuhiro ; Goi, Takanori ; Seto, Shun ; Tsujikawa, Tetsuya ; Sawai, Katsuji ; Okazawa, Hidehiko ; Kurebayashi, Hidetaka</creator><creatorcontrib>Morikawa, Mitsuhiro ; Goi, Takanori ; Seto, Shun ; Tsujikawa, Tetsuya ; Sawai, Katsuji ; Okazawa, Hidehiko ; Kurebayashi, Hidetaka</creatorcontrib><description>Background: We aimed to evaluate the diagnostic accuracy of 2-[[sup.18]F]-fluoro-2-deoxy-D-glucose positron emission tomography/magnetic resonance imaging ([[sup.18]F]FDG PET/MRI) for preoperative staging and usefulness of the detection of extramural vascular invasion (EMVI) for predicting metastasis in rectal cancer. Methods: Twenty-three patients underwent pretreatment [[sup.18]F]FDG PET/MRI, including early-delayed and extended PET and dedicated pelvic MRI without using anticonvulsant or contrast agents. Seven patients received preoperative treatment and all subsequently underwent surgery. Clinical cancer stages were evaluated using postoperative histopathology as a reference. PET/MR-defined EMVI (pmrEMVI) and pathological (p) TN stages were correlated with disease progression for a maximum of 2 years. Results: Of 16 patients without preoperative treatment, 10 had pT3, 4 tumors, 7 had pN1-3 lymph nodes, and 5 had synchronous metastases (SM; liver, lung, inguinal node). The sensitivity, specificity, and accuracy of PET/MRI were 90%, 67%, and 81% for T staging (T1, 2 vs. T3, 4), and 89%, 100%, and 94% for N staging (N0 vs. N1-3), respectively. Patient-based accuracy for SM staging was 100% (4/4). Of 23 patients, 6 were positive for pmrEMVI and 4 had metachronous metastases or local recurrence (MM; pelvic node, brain, lung, skin) during the follow-up periods. Five of the 6 pmrEMVI-positive patients had SM and/or MM (odds ratio = 37.5). Among pT, pN, and pmrEMVI, pmrEMVI-positivity was the only significant predictor for poorer progression-free survival (p &lt; 0.05). Conclusions: [[sup.18]F]FDG PET/MRI according to our suggested protocol is a one-stop, non-contrast, and valid diagnostic method for rectal cancer staging, and pmr­EMVI can be used as an imaging biomarker for predicting metastases. Keywords: Positron emission tomography/magnetic resonance imaging, Rectal cancer, Staging, Extramural vascular invasion, Metastasis</description><identifier>ISSN: 0030-2414</identifier><identifier>DOI: 10.1159/000522205</identifier><language>eng</language><publisher>S. Karger AG</publisher><subject>Cancer ; Colorectal cancer ; Development and progression ; Diagnosis ; Evaluation ; Metastasis ; Methods ; Oncology, Experimental ; PET imaging ; Risk factors ; Tumor staging</subject><ispartof>Oncology, 2022-04, Vol.100 (4), p.212</ispartof><rights>COPYRIGHT 2022 S. Karger AG</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Morikawa, Mitsuhiro</creatorcontrib><creatorcontrib>Goi, Takanori</creatorcontrib><creatorcontrib>Seto, Shun</creatorcontrib><creatorcontrib>Tsujikawa, Tetsuya</creatorcontrib><creatorcontrib>Sawai, Katsuji</creatorcontrib><creatorcontrib>Okazawa, Hidehiko</creatorcontrib><creatorcontrib>Kurebayashi, Hidetaka</creatorcontrib><title>Feasibility of [[sup.18]F]FDG PET/MRI with Early-Delayed and Extended PET as One-Stop Imaging for Staging and Predicting Metastasis in Rectal Cancer</title><title>Oncology</title><description>Background: We aimed to evaluate the diagnostic accuracy of 2-[[sup.18]F]-fluoro-2-deoxy-D-glucose positron emission tomography/magnetic resonance imaging ([[sup.18]F]FDG PET/MRI) for preoperative staging and usefulness of the detection of extramural vascular invasion (EMVI) for predicting metastasis in rectal cancer. Methods: Twenty-three patients underwent pretreatment [[sup.18]F]FDG PET/MRI, including early-delayed and extended PET and dedicated pelvic MRI without using anticonvulsant or contrast agents. Seven patients received preoperative treatment and all subsequently underwent surgery. Clinical cancer stages were evaluated using postoperative histopathology as a reference. PET/MR-defined EMVI (pmrEMVI) and pathological (p) TN stages were correlated with disease progression for a maximum of 2 years. Results: Of 16 patients without preoperative treatment, 10 had pT3, 4 tumors, 7 had pN1-3 lymph nodes, and 5 had synchronous metastases (SM; liver, lung, inguinal node). The sensitivity, specificity, and accuracy of PET/MRI were 90%, 67%, and 81% for T staging (T1, 2 vs. T3, 4), and 89%, 100%, and 94% for N staging (N0 vs. N1-3), respectively. Patient-based accuracy for SM staging was 100% (4/4). Of 23 patients, 6 were positive for pmrEMVI and 4 had metachronous metastases or local recurrence (MM; pelvic node, brain, lung, skin) during the follow-up periods. Five of the 6 pmrEMVI-positive patients had SM and/or MM (odds ratio = 37.5). Among pT, pN, and pmrEMVI, pmrEMVI-positivity was the only significant predictor for poorer progression-free survival (p &lt; 0.05). Conclusions: [[sup.18]F]FDG PET/MRI according to our suggested protocol is a one-stop, non-contrast, and valid diagnostic method for rectal cancer staging, and pmr­EMVI can be used as an imaging biomarker for predicting metastases. Keywords: Positron emission tomography/magnetic resonance imaging, Rectal cancer, Staging, Extramural vascular invasion, Metastasis</description><subject>Cancer</subject><subject>Colorectal cancer</subject><subject>Development and progression</subject><subject>Diagnosis</subject><subject>Evaluation</subject><subject>Metastasis</subject><subject>Methods</subject><subject>Oncology, Experimental</subject><subject>PET imaging</subject><subject>Risk factors</subject><subject>Tumor staging</subject><issn>0030-2414</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNpNjE1rwkAQhnNoodb20H-wUOgturtx83EUTaygKOpNRCab2bglbiS70vo_-oMbsQdhYObhfeb1vDdGe4yJpE8pFZxzKh68DqUB9fmADZ68Z2u_2igSg7Dj_WYIVue60u5CakW2W3s-9Vi8y3bZeEKW6aY_X03Jt3YHkkJTXfwxVnDBgoApSPrj0BQttB4BSxYG_bWrT2R6hFKbkqi6IWt3u68PywYLLd0V5-jAtqMt0YasUDqoyAiMxObFe1RQWXz9311vk6Wb0ac_W0ymo-HML0US-3mghApjFsqiCBOhFPCYURmyKIpzzgqOEEoaSWRMBZEIQpQ8BqSoEITMVdD13m-1JVS410bVrgF51FbuhxFNEsrDOG6tjzvrgFC5g62rs9O1sffiHw5FcI4</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Morikawa, Mitsuhiro</creator><creator>Goi, Takanori</creator><creator>Seto, Shun</creator><creator>Tsujikawa, Tetsuya</creator><creator>Sawai, Katsuji</creator><creator>Okazawa, Hidehiko</creator><creator>Kurebayashi, Hidetaka</creator><general>S. Karger AG</general><scope/></search><sort><creationdate>20220401</creationdate><title>Feasibility of [[sup.18]F]FDG PET/MRI with Early-Delayed and Extended PET as One-Stop Imaging for Staging and Predicting Metastasis in Rectal Cancer</title><author>Morikawa, Mitsuhiro ; Goi, Takanori ; Seto, Shun ; Tsujikawa, Tetsuya ; Sawai, Katsuji ; Okazawa, Hidehiko ; Kurebayashi, Hidetaka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g598-b3f5f6816cdd695ffa2810c61778b21d2ea6c07ce11f37536ec28ae0efea5cbf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cancer</topic><topic>Colorectal cancer</topic><topic>Development and progression</topic><topic>Diagnosis</topic><topic>Evaluation</topic><topic>Metastasis</topic><topic>Methods</topic><topic>Oncology, Experimental</topic><topic>PET imaging</topic><topic>Risk factors</topic><topic>Tumor staging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morikawa, Mitsuhiro</creatorcontrib><creatorcontrib>Goi, Takanori</creatorcontrib><creatorcontrib>Seto, Shun</creatorcontrib><creatorcontrib>Tsujikawa, Tetsuya</creatorcontrib><creatorcontrib>Sawai, Katsuji</creatorcontrib><creatorcontrib>Okazawa, Hidehiko</creatorcontrib><creatorcontrib>Kurebayashi, Hidetaka</creatorcontrib><jtitle>Oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morikawa, Mitsuhiro</au><au>Goi, Takanori</au><au>Seto, Shun</au><au>Tsujikawa, Tetsuya</au><au>Sawai, Katsuji</au><au>Okazawa, Hidehiko</au><au>Kurebayashi, Hidetaka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Feasibility of [[sup.18]F]FDG PET/MRI with Early-Delayed and Extended PET as One-Stop Imaging for Staging and Predicting Metastasis in Rectal Cancer</atitle><jtitle>Oncology</jtitle><date>2022-04-01</date><risdate>2022</risdate><volume>100</volume><issue>4</issue><spage>212</spage><pages>212-</pages><issn>0030-2414</issn><abstract>Background: We aimed to evaluate the diagnostic accuracy of 2-[[sup.18]F]-fluoro-2-deoxy-D-glucose positron emission tomography/magnetic resonance imaging ([[sup.18]F]FDG PET/MRI) for preoperative staging and usefulness of the detection of extramural vascular invasion (EMVI) for predicting metastasis in rectal cancer. Methods: Twenty-three patients underwent pretreatment [[sup.18]F]FDG PET/MRI, including early-delayed and extended PET and dedicated pelvic MRI without using anticonvulsant or contrast agents. Seven patients received preoperative treatment and all subsequently underwent surgery. Clinical cancer stages were evaluated using postoperative histopathology as a reference. PET/MR-defined EMVI (pmrEMVI) and pathological (p) TN stages were correlated with disease progression for a maximum of 2 years. Results: Of 16 patients without preoperative treatment, 10 had pT3, 4 tumors, 7 had pN1-3 lymph nodes, and 5 had synchronous metastases (SM; liver, lung, inguinal node). The sensitivity, specificity, and accuracy of PET/MRI were 90%, 67%, and 81% for T staging (T1, 2 vs. T3, 4), and 89%, 100%, and 94% for N staging (N0 vs. N1-3), respectively. Patient-based accuracy for SM staging was 100% (4/4). Of 23 patients, 6 were positive for pmrEMVI and 4 had metachronous metastases or local recurrence (MM; pelvic node, brain, lung, skin) during the follow-up periods. Five of the 6 pmrEMVI-positive patients had SM and/or MM (odds ratio = 37.5). Among pT, pN, and pmrEMVI, pmrEMVI-positivity was the only significant predictor for poorer progression-free survival (p &lt; 0.05). Conclusions: [[sup.18]F]FDG PET/MRI according to our suggested protocol is a one-stop, non-contrast, and valid diagnostic method for rectal cancer staging, and pmr­EMVI can be used as an imaging biomarker for predicting metastases. Keywords: Positron emission tomography/magnetic resonance imaging, Rectal cancer, Staging, Extramural vascular invasion, Metastasis</abstract><pub>S. Karger AG</pub><doi>10.1159/000522205</doi></addata></record>
fulltext fulltext
identifier ISSN: 0030-2414
ispartof Oncology, 2022-04, Vol.100 (4), p.212
issn 0030-2414
language eng
recordid cdi_gale_infotracmisc_A709902688
source Karger Journals
subjects Cancer
Colorectal cancer
Development and progression
Diagnosis
Evaluation
Metastasis
Methods
Oncology, Experimental
PET imaging
Risk factors
Tumor staging
title Feasibility of [[sup.18]F]FDG PET/MRI with Early-Delayed and Extended PET as One-Stop Imaging for Staging and Predicting Metastasis in Rectal Cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T02%3A21%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Feasibility%20of%20%5B%5Bsup.18%5DF%5DFDG%20PET/MRI%20with%20Early-Delayed%20and%20Extended%20PET%20as%20One-Stop%20Imaging%20for%20Staging%20and%20Predicting%20Metastasis%20in%20Rectal%20Cancer&rft.jtitle=Oncology&rft.au=Morikawa,%20Mitsuhiro&rft.date=2022-04-01&rft.volume=100&rft.issue=4&rft.spage=212&rft.pages=212-&rft.issn=0030-2414&rft_id=info:doi/10.1159/000522205&rft_dat=%3Cgale%3EA709902688%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A709902688&rfr_iscdi=true